AMACR/p504S在胃癌中的表达及其临床意义

目的:探讨AMACR在胃癌中的表达及其与临床病理特征之间的关系.方法:应用免疫组化EnVision法检测78例胃癌组织中AMACR/p504s的表达.结果:胃癌组织中AMACR/p504s的阳性表达率为42.3％(33/78).胃癌中AMACR/p504s的表达在肠型胃癌中表达为61.3％,明显高于弥漫型胃癌29.6％,差异有显著性(P＜ 0.01);AMACR/p504s在高、中和低分化腺癌的阳性表达率分别为73.3％、48.3％和23.5％,差异有显著性(P＜0.01).胃腺癌中AMACR/p504s的表达与肿瘤浸润深度、淋巴结转移和临床分期均无关(P＞0.05).结论:AMACR/p504s的表达与胃癌Lauren分型和分化程度密切相关,可能参与了胃肠型腺癌的发生.

Expression of a-Methylacyl coenzyme A racemase in gastric carcinoma and its clinical significance

Objective To explore the expression of a-Methylacyl coenzyme A racemase(AMACR) in gastric carcinoma and its relationship with clinicopathologic features.Methods Expression of AMACR in 78 cases of gastric carcinoma were detected by EnVision immunohistochemical technique.Results The expression rate of AMACR/p504s in gastric carcinoma was 42.3%(33/78).Expression of AMACR/p504s in intestinal-type adenocarcinoma was 61.3%,it was higher than that in diffuse-type adenocarcinoma(29.6%,P < 0.01).AMACR/p504s expression in well,moderately,and poorly-differentiated adenocarcinoma were 73.3%,48.3% and 23.5%,respectively.There was significant difference among three groups(P < 0.01).Expression of AMACR/p504s in gastric carcinoma was unrelated to the depth of invasion,lymph node metastasis and clinical stage(P > 0.05).Conclusions Expression of AMACR/p504s may be correlated with Lauren type and differentiation and may be involved in gastric carcinogenesis.